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Abstract
Background and purpose Prolonged Holter monitoring of
patients with cerebral ischemia increases the detection rate of
paroxysmal atrial fibrillation (PAF); this leads to improved
antithrombotic regimens aimed at preventing recurrent
ischemic strokes. The aim of this study was to compare a
7-day-Holter monitoring (7-d-Holter) alone or in combina-
tion with prior selection via transthoracic echocardiography
(TTE) to a standard 24-h-Holter using a cost-utility analysis.
Methods Lifetime cost, quality-adjusted life years (QALY),
and incremental cost-effectiveness ratios (ICER) were
estimated for a cohort of patients with acute cerebral
ischemia and no contraindication to oral anticoagulation.
A Markov model was developed to simulate the long-term
course and progression of cerebral ischemia considering
the different diagnostic algorithms (24-h-Holter, 7-d-Hol-
ter, 7-d-Holter after preselection by TTE). Clinical data for
these algorithms were derived from the prospective
observational Find-AF study (ISRCTN 46104198).
Results Predicted lifelong discounted costs were 33,837 €
for patients diagnosed by the 7-d-Holter and 33,852 € by
the standard 24-h-Holter. Cumulated QALYs were 3.868
for the 7-d-Holter compared to 3.844 for the 24-h-Holter.
The 7-d-Holter dominated the 24-h-Holter in the base-case
scenario and remained cost-effective in extensive sensi-
tivity analysis of key input parameter with a maximum of
8,354 €/QALY gained. Preselecting patients for the 7-d-
Holter had no positive effect on the cost-effectiveness.
Conclusions A 7-d-Holter to detect PAF in patients with
cerebral ischemia is cost-effective. It increases the detec-
tion which leads to improved antithrombotic regimens;
therefore, it avoids recurrent strokes, saves future costs,F. Mayer and R. Stahrenberg contributed equally and share first
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and decreases quality of life impairment. Preselecting
patients by TTE does not improve cost-effectiveness.
Keywords Atrial fibrillation  Stroke  Holter
monitoring  Cost-effectiveness  Markov model
Introduction
Stroke poses a heavy economic burden, accounting for *2
to 7 % of total health expenditures that is equivalent to
0.15–0.36 % of the gross domestic product of western
societies [1–3]. Atrial fibrillation (AF) is a frequent cause
of ischemic stroke (IS) [4] and patients with AF have an
almost fivefold increased risk of suffering a second stroke
[5, 6]. Better detection of paroxysmal atrial fibrillation
(PAF) by prolonged Holter monitoring [7] can be expected
to improve secondary prevention through optimized sec-
ondary preventive regimens, namely, oral anticoagulation
for those with PAF [8–10]. However, 7-day-Holter moni-
toring (7-d-Holter) is associated with increased costs. We
therefore proposed to select patients with a high pre-test
probability for PAF for extended Holter monitoring by
applying a recently described index of left atrial enlarge-
ment and impaired left atrial function as measured by
transthoracic echocardiography [11]. We aimed to evaluate
the cost-effectiveness of three diagnostic strategies to detect
PAF after acute cerebral ischemia: (a) standard 24-h-Holter
monitoring (24-h-Holter), (b) 7-d-Holter, or (c) 7-d-Holter in
a subgroup only, preselected by TTE (TTE/7-d-Holter).
Methods
Study population
The Markov model considers a hypothetical cohort of
patients after the first ever IS or transient ischemic attack
(TIA) presenting in sinus rhythm. In this cohort, AF has not
previously been diagnosed and no contraindication of OAC
therapy exists. The mean age is 68 years. Further details on
the FIND-AF (ISRCTN 46104198) trial and its study
population have been published elsewhere [7].
Model structure and health states
We developed a Markov microsimulation model to estimate
lifetime costs, cumulative quality-adjusted life years (QA-
LYs), and the incremental cost-effectiveness ratio (ICER) of
alternative diagnostic algorithms using TreeAge Pro Suite
2009 (TreeAge Software, Inc., Williamstown, Massachu-
setts). Markov modeling is a suitable technique in decision
problems that involve risks and costs that can recur and/or
change over time [12]. Our model analysis considered a
lifelong horizon and we chose a cycle length of 6 months.
The simulation was ended once the fraction of the cohort
remaining alive fell below a threshold of 1 %. Costs of care
were estimated from a third party payers’ perspective. Costs
and quality of life estimates were discounted at a rate of 3 %
[12]. After screening for PAF using 24-h-Holter, 7-d-Holter
or TTE/7-d-Holter, patients entered a Markov model that
simulated the long-term disease course and progression of
cerebral ischemia, adverse events such as recurrent ISs,
intracranial hemorrhage (ICH) or fatal strokes as well as
dying from other causes. The risk of IS recurrence and ICH
depended on the patient’s age and anticoagulation regimen.
Our simulation model distinguished between seven perma-
nent health states, namely TIA, minor stroke, major stroke,
recurrent minor or major stroke, ICH and death. The general
model structure and possible transitions between permanent
health states are depicted in Figs. 1 and 2.
Transthoracic echocardiography and detection rates
of Holter monitoring
Our model compares three diagnostic algorithms/strategies
to detect PAF. These strategies differed in detection rates
of PAF, as derived from the FIND-AF cohort (Table 1).
Prevalence of detected PAF was 13.3 % for 7-d-Holter
[11]. Within our comparative approach, we considered 7-d-
Holter to have 100 % sensitivity for PAF. The 24-h-Holter
only detected PAF in 46.4 % of the patients who were
positive using 7-d-Holter, leaving 53.6 % of the PAF cases
undetected [7]. After preselecting patients for the 7-d-
Holter using TTE (51.1 % of all patients had LAVI/
a0 [ 2.3 and therefore qualified for 7-d-Holter), the prev-
alence of PAF detected by 7-d-Holter was 23.9 %. Using
the cut-off value of LAVI/a0 B 2.3 as measured by TTE
yielded 2.2 % of false negatives in FIND-AF [11]. The
model considers patients receiving oral anticoagulation in
form of warfarin or aspirin (ASS) as the most commonly
used antiplatelet [13]. When PAF was detected by the 24-h-
Holter or the 7-d-Holter, the treatment regimen was
changed to warfarin, while all PAF-negative patients are
treated with ASS (Fig. 1).
Probability of adverse outcomes
To obtain key model inputs for IS/TIA recurrence, we
reviewed relevant clinical trials and meta-analyses that
investigated warfarin and aspirin therapy for secondary
stroke prevention in patients with AF: 6.3 % annual rate of
IS/TIA on ASS (false-negative detection) and a 0.48 rela-
tive risk of IS/TIA with warfarin compared to ASS
resulting in 3.02 % annual rate on warfarin [14, 15]. Fur-
thermore, we modeled a 4.8 relative risk of recurrent
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IS/TIA for patients with PAF compared to PAF-negative
patients resulting in an annual recurrence rate of 1.31 % for
PAF-negative patients treated with ASS [6, 14]. Annual
rates for IS/TIA were increased by a factor of 1.4 per
decade of life (multiplicative adjustment) to account for
increasing age [16]. To account for different stroke severity
levels, we classified IS into four categories: TIA, minor
stroke, major stroke, and fatal stroke [17]. We considered
an annual rate hemorrhagic stroke/intracranial hemorrhage
of 1.28 % for warfarin and 0.76 % for aspirin (relative risk
ASS vs. warfarin: 0.59) [15, 18]. Hemorrhage-related event
rates were increased by a factor of 1.97 per decade of life
(crude relative risk for every 10-year increase in age) [19].
Similarly to our consideration of different IS levels, we
classified ICH into fatal and non-fatal events with a base-
case mortality of OAC-associated ICH of 60 % [20].
Table 1 depicts all variables used in detail.
Background mortality
Background mortality was modeled using age specific
mortality rates adjusted for the increased risk of dying after
cerebral ischemia [21]. These values reflect 6-month event
rates after the initial event (Table 1) [22].
Fig. 1 Decision model. It considers three diagnostic algorithms:
24-h-Holter monitoring referred to as standard diagnostic, 7-d-Holter
and 7-d-Holter preceded by transthoracic echocardiography (TTE).
Section displays false-negative results of 24-h-Holter and asterisk
indicates false-negative results of TTE and, therefore, patients falsely
treated with antiplatelets only. AF?/AF- patients with/without atrial
fibrillation as a result of the three diagnostic algorithms, ASS aspirin,
ICH intracranial hemorrhage, IS ischemic stroke, LAVI left atrial
volume index, OAC oral anticoagulation, TIA transient ischemic
attack, TTE transthoracic echocardiography
Fig. 2 Possible transitions between permanent health states. Based
on stroke severity within the FIND-AF cohort, patients start in one of
the defined states namely TIA, minor stroke, major stroke, and
recurrent minor or major stroke. Then patients cycle between states
until death. The cycle length is 6 months. A transition to death from
any cause (background mortality or fatal strokes) is possible from any
state. ICH intracranial hemorrhage, IS ischemic stroke, TIA transient
ischemic attack
Clin Res Cardiol (2013) 102:875–884 877
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Table 1 Model variables: base case and range used in sensitivity analysis
Input variables Base case Range References
Atrial fibrillation–detection parametersa (%)
Proportion of patients with LAVI/a0 B 2.3 48.9 (44.01–53.79) [11, 7], [FIND-AF]
Proportion of patients with LAVI/a0 [ 2.3 51.1 (45.99–56.21) [11, 7], [FIND-AF]
Negative predictive value (LAVI/a0 B 2.3) 97.8 (88.02–100.0) [11, 7], [FIND-AF]
False negatives (LAVI/a0 B 2.3) 2.2 (1.98–2.42) [11, 7], [FIND-AF]
Prevalence of AF (no preceding TTE) 13.3 (11.97–14.63) [11, 7], [FIND-AF]
Prevalence of AF after preceding TTE 23.9 (21.51–26.29) [11, 7], [FIND-AF]
Sensitivity of 24-h-Holter 46.4 (41.76–51.04) [11, 7], [FIND-AF]
False negatives (24-h-Holter) 53.6 [48.24–58.96] [11, 7], [FIND-AF]
Ischemic stroke parameters
Annual rate of stroke with warfarin and AFa,b (%) 3.02 (2.72–3.32) [14, 15]
Ischemic strokes with warfarin that were
Fatal (%) 8.2 (8.2–10.1) [17]
Major (disabling) (%) 40.2 (40.2–41.7) [17]
Minor (%) 42.5 (34.8–42.5) [17]
TIA/no residua (%) 9.1 (9.1–13.3) [17]
Relative risk of stroke with warfarin compared with aspirin 0.48 (0.37–0.63) [15]
Annual rate of stroke with aspirin and AFb (%) 6.3 (5.67–6.93) [14]
Relative risk of stroke with AF compared to without AF 4.8 (2.0–6.0) [6]
Annual rate of stroke with aspirin and without AFb (%) 1.31 (1.18–1.44) [6, 14]
Ischemic strokes with aspirin that were:
Fatal (%) 17.9 (10.1–17.9) [17]
Major (disabling) (%) 30.0 (30.0–41.7) [17]
Minor (%) 41.0 (34.8–41.0) [17]
TIA/no residua (%) 11.0 (11.0–13.3) [17]
Hemorrhagic stroke parameters
Annual rate of hemorrhagic stroke/ICH with warfarina,c (%) 1.28 (1.15–1.41) [18]
Relative risk of hemorrhage with aspirin compared with warfarin 0.59 (0.5–0.7) [15]
Annual rate of hemorrhagic stroke/ICH with aspirinc (%) 0.76 (0.68–0.84) [15, 18]
Mortality after hemorrhagic stroke/ICH 0.6 (0.46–0.68) [20]
Mortality parameters, excluding acute strokea,d
Months 0–6 (%) 10.24 (9.22–11.26) [21]
Months 6–12 (%) 6.20 (5.58–6.82) [21]
Year 2–5 after stroke (%) 2.96 (2.66–3.26) [21]
Year 6–15 after stroke (%) 6.76 (6.08–7.44) [21]
Year 16? after stroke (%) 9.15 (8.23–10.06) [21]
Quality of life estimatesa
Ischemic stroke/major 0.52 (0.47–0.57) [32]
Ischemic stroke/minor 0.87 (0.78–0.96) [32]
Recurrent stroke (2nd disabling stroke) 0.12 (0.11–0.13) [31]
TIA 0.9 (0.81–0.99) [33]
Hemorrhagic stroke/intracranial hemorrhage (ICH) 0.62 (0.55–0.67) [34]
AF atrial fibrillation, ICH intracranial hemorrhage, LAVI left atrial volume index, TTE transthoracic echocardiography TIA transient ischemic attack
a Range ±10 %
b Rate of stroke increased by the factor 1.4 per decade of life, compounded for every 6-month cycle
c Rate of hemorrhagic stroke/ICH increased by the factor 1.97 per decade of life, compounded for every 6-month cycle
d Mortality parameters adapted to a cycle length of 6 months
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Costs estimates
Since Find-AF was conducted in Germany, direct costs
were estimated in a way such that it reflected the German
health care system, i.e., DRG rate payments for hospital-
ization. All costs were adjusted to 2011 Euro using German
consumer price indices.
Acute care
Costs of acute care after recurrent events include those for
emergency ambulance transportation, hospitalization, and
inpatient (acute) rehabilitation (Table 2). Cost data which
could not be extracted from the literature such as direct
costs for acute hospitalization of patients with TIA were
calculated using a nationwide base-rate of 2,936 € and a
relative (cost) weight based on the appropriate DRG (B69)
taken from the institute for the hospital remuneration sys-
tem (InEK Begleitforschung) in Germany [23, 24]. The
base rate was calculated by weighting the base rates of all
German federal states (Verband der Ersatzkassen e. V.) by
their total case mix as published by the InEK. Costs of
acute hospitalization in patients with hemorrhagic strokes
were calculated using a web DRG grouper based on the
appropriate ICD as recommended by the German coding
guidelines for neurological diseases (ICD I61, I69.1 und
D68.30) and the nationwide base-rate [25, 26].
Post-acute care
For every subsequent 6-month cycle after cerebral ische-
mia we included costs for emergency ambulance trans-
portation, hospitalization, outpatient care, medication,
rehabilitation, reintegration, and nursing care (Table 3).
Regarding post-acute costs of care, we distinguished
between costs that occurred during the months 1–6, 7–12
and every following 6 months period after the initial event
[27]. Calculation of medication costs was restrained to the
different anticoagulation regimens under the assumption
that medications for patients with PAF differ from those
without PAF in the antithrombotic regimen only, by using
the appropriate costs per defined daily dose (DDD) as
published in the Arzneimittelverordnungsreport 2010 and
adjusted these costs to reflect our cycle length [28]. INR
measurements were not calculated separately, since they
were included in the costs of outpatient care as reported by
Bru¨ggenju¨rgen et al. [27]. Post-acute costs varied by dif-
ferent health states and were considered every 6-month
period after the initial event (Table 3). We assumed that
rehabilitation, reintegration, and permanent nursing care
were not necessary in patients who were not permanently
compromised, and thus, did not include these costs in our
analysis. Post-acute costs for TIA patients were limited to
the costs of both anticoagulation regimens. Since there was
limited data available considering post-acute costs of
patients after ICH, we calculated these costs based on the
relative difference in the utilities for patients after major IS
and ICH (cost reduction 19.23 %).
Resource costs of prolonged Holter monitoring
For the last 21 patients who had received the 7-d-Holter in
Find-AF, detailed data on resource utilization were col-
lected and compared to the 24-h-Holter. Based on these
data, additional costs were added once for every patient in
the 7-d-Holter strategy and those patients who received
7-d-Holter in the TTE/7-d-Holter strategy. To estimate
costs for medical staff, costs per minute were calculated
according to the gross annual salary and mean annual
working time of medical practitioners and medical tech-
nical assistants in Germany [29, 30]. Preceding TTE was
considered to be a standard procedure for patients with
Table 2 Cost variables for acute treatment: base case and range used in sensitivity analysis
Input variables Base case Range References
Cost of acute carea,b (€)
Ischemic stroke (with AF) 7,315 (6,584–8,047) [27, 42]
Ischemic stroke (without AF) 6,224 (5,602–6,846) [27, 42]
Ischemic stroke (fatal) 4,031 (3,628–4,434) [43]
Hemorrhagic stroke 5,546 (4,991–6,100) [23, 25–27]
Hemorrhagic stroke (fatal) 3,652 (3,287–4,017) [43]
Transient ischemic attack (TIA) 2,637 (2,373–2,900) [24, 27]
Additional resource cost 7-d vs. 24-h-Holtera (€) 34 (20–165) [FIND-AF], [29]
Cost discounting rate (%) 3 [1–5] [12]
AF atrial fibrillation, TIA transient ischemic attack
a Presented in 2011 Euros
b Range ±10 %
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acute cerebral ischemia during hospitalization resulting in
no additional costs (Table 2).
Quality of life estimates
To calculate the quality-adjusted survival, literature search
was done to obtain suitable quality of life estimates (util-
ities) for each health state modeled (Table 1) [17, 31]. For
major stroke, the mean utility was 0.52 and 0.87 for minor
stroke [32]. For recurrent disabling strokes—i.e., a second
major stroke or a major stroke following ICH—we used a
mean utility of 0.12 [31]. For patients after TIA we used a
utility of 0.9 and for ICH 0.62 [33, 34]. The utility of death
from any cause was 0. Patients remained in their original
state when a recurrent event was less severe (e.g., TIA in
patients with previous major stroke).
Sensitivity analyses
We performed sensitivity analyses for all variables used in
the model. Where no data about the plausible range of the
input variable were available it was varied ±10 %.
Results
Base-case analysis
In the base-case scenario, the discounted quality-adjusted
life expectancy in a 68-year-old patient with acute IS or TIA
ranged from 3.833 QALYs for patients with 24-h-Holter to
3.842 QALYs with TTE/7-d-Holter and 3.844 QALYs with
7-d-Holter. Mean discounted lifetime costs ranged from
32,887 € for the TTE/7-d-Holter to 32,912 € for the 24-h-
Holter (Table 4); 24-h-Holter was dominated by 7-d-Holter
and TTE/7-d-Holter, respectively. The latter strategy had
slightly lower mean lifetime costs, saving 8.9 € compared
to the 7-d-Holter. In the base-case scenario this resulted in
additional costs per QALY gained of 5,354 €/QALY for the
7-d-Holter compared to the TTE/7-d-Holter.
In a cohort of 10,000 patients with acute cerebral
ischemia, the 7-d-Holter detected 710 more cases of PAF
than the 24-h-Holter; this resulted in a gain of 7.85 QA-
LYs, or 82 more cases than TTE/7-d-Holter, resulting in
0.14 QALYs gained. Over the patients’ lifetime, the 7-d-
Holter prevented 155 IS compared to the 24-h-Holter but
oral anticoagulation caused an additional 26 ICH (7-d-
Holter vs. TTE/7-d-Holter: IS: -3; ICH: ?5).
Sensitivity analysis
Examining the key model input parameters over a wide
range demonstrated that the 7-d-Holter was cost-effective
or dominant in most scenarios when compared to the 24-h-
Holter (Fig. 3). A variation of stroke severity of recurrent
IS of ASS- or OAC-treated patients influenced the incre-
mental cost per QALY, but never exceeded 3,022 € per
QALY gained. A 10 % increase in the annual risk of
recurrent stroke in PAF-positive patients treated with ASS
led to the dominance of the 7-d-Holter over the 24-h-
Holter, while a 10 % reduction resulted in an ICER of
1,131 €/QALY.
Two-way sensitivity analysis investigating the annual
recurrence of IS and ICH yielded an ICER of 15,145 €/
QALY comparing the use of a 7-d-Holter to a 24-h-Holter
when both event rates were increased by 20 %; a decrease
of 10 % demonstrated the dominance of the 7-d-Holter
(Table 4).
Variation in costs had the most influence on changes in
the ICER; a 10 % increase in post-acute costs for patients
Table 3 Cost variables: base case and range used in sensitivity analysis
Post-acute cost of carea,b (€) Month 1–6 after event Month 7–12 after event Every following 6-month period
after year 1
References
Base case Range Base case Range Base case Range
Ischemic stroke (major, aspirin) 7,224 (6,503–7,948) 6,420 (5,778–7,062) 5,635 (5,072–6,199) [27, 28]
Ischemic stroke (major, warfarin) 7,265 (6,534–7,986) 6,460 (5,809–7,099) 5,674 (5,102–6,236) [27, 28]
Ischemic stroke (minor, aspirin) 2,075 (1,868–2,283) 1,599 (1,439–1,759) 1,123 (1.011–1.235) [27, 28]
Ischemic stroke (minor, warfarin) 2,115 (1,899–2,321) 1,639 (1,470–1,796) 1,163 (1,042–1,274) [27, 28]
Hemorrhagic stroke (aspirin) 5,837 (5,252–6,420) 5,186 (4,667–5,704) 4,551 (4,096–5,006) [27, 28]
Hemorrhagic stroke (warfarin) 5,871 (5,278–6,450) 5,220 (4,692–5,734) 4,585 (4,121–5,037) [27, 28]
TIA (aspirin) 8 (7.2–8.8) 8 (7.2–8.8) 8 (7.2–8.8) [28]
TIA (warfarin) 42 (37.8–46.2) 42 (37.8–46.2) 42 (37.8–46.2) [28]
TIA transient ischemic attack
a Presented in 2011 Euros, differentiated by stroke severity and anticoagulation regimen
b Range ±10 %
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Table 4 Projected costs and QALYs for patients after ischemic stroke or TIA under base-case conditions and by varying risk of ischemic/
hemorrhagic stroke
Rate of IS and ICH with
warfarin (% per year)
ECG setting Cost (€) Incremental
cost (€)
QALYs Incremental effect
(QALYs)
ICER
(€ per QALY)
IS: 2.72 %, ICH: 1.15 % TTE / 7-d-Holter 32,854.4 – 3.846 – Reference
7-d-Holter 32,860.5 6.1 3.848 0.0020 2978.37
24-h-Holter 32,895.9 35.4 3.835 -0.0135 Dominated
IS: 3.02 %, ICH: 1.28 % TTE / 7-d-Holter 32,886.9 – 3.842 Reference
Base case 7-d-Holter 32,895.8 8.9 3.844 0.0017 5,353.92
24-h-Holter 32,912.3 16.5 3.833 -0.0111 Dominated
IS: 3.32 %, ICH: 1.41 % TTE / 7-d-Holter 32,918.0 – 3.838 – Reference
24-h-Holter 32,928.0 10.0 3.831 -0.0073 Dominated
7-d-Holter 32,929.7 11.7 3.839 0.0013 8,957.96
IS: 3.62 %, ICH: 1.54 % 24-h-Holter 32,943.2 – 3.829 – Reference
TTE/7-d-Holter 32,948.0 4.9 3.834 0.0053 913.25
7-d-Holter 32,962.4 14.3 3.835 0.0009 15,145.35
IS ischemic stroke, ICH intracranial hemorrhage, TTE transthoracic echocardiography, QALY quality-adjusted life year, ICER incremental cost-
effectiveness ratio
Fig. 3 Univariate sensitivity
analysis on most influential
variables 7-d vs. 24-h-Holter
monitoring: incremental cost-
effectiveness ratio (ICER).
Figure 3 displays the influence
of a variation of variables used
in the model on the ICER of the
7-d vs. 24-h-Holter. The vertical
line represents the base-case
scenario. Negative ICERs imply
dominance of the 7-d-Holter
and positive ICERs show the
maximal costs per QALY
gained. AF atrial fibrillation,
ASS aspirin, IS ischemic stroke,
OAC oral anticoagulation,
QALY quality-adjusted life year,
TIA transient ischemic attack
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after major IS and warfarin therapy estimated an ICER of
16,911 €/QALY, while a 10 % decrease in post-acute costs
for similar patients treated with ASS yielded an ICER of
16,945 €/QALY. Extended use of Holter monitoring
affected the ICER in two ways, a higher detection rate and
extra costs due to the additional use of personnel and
material resources. We varied the prevalence of PAF
detected by 7-d-Holter from 8 to 20 %, yielding an ICER
of 527 €/QALY at 8 %. Higher detection rates of up to
20 % enhanced the dominance of 7-d-Holter with a
threshold of 8.9 % beyond which the 7-d-Holter was less
expensive than the 24-h-Holter. Raising additional resource
costs for 7-d-Holter to 165 € resulted in an ICER of
10,385 €/QALY. The 7-d-Holter remained dominant up to
a threshold of 50.2 €.
With regard to test accuracy, 7-d-Holter remained cost-
effective when compared to the TTE/7-d-Holter in most
scenarios. Beyond a negative predictive value of 98.9 %
for the preceding TTE, the TTE/7-d-Holter became the
dominant strategy. An increase of PAF-prevalence without
TTE up to 20 % resulted in dominance of 7-d-Holter; a
decrease of PAF-prevalence with preceding TTE resulted
in an ICER 7-d-Holter vs. TTE/7-d-Holter of 19,491 €/
QALY at 21.5 %. Raising monitoring costs to 165 €
increased the incremental cost-effectiveness ratio to
43,799 € per QALY gained because of the higher propor-
tion of patients being examined by 7-d-Holter.
Discussion
Our analysis demonstrated that using the 7-d-Holter instead
of the standard 24-h-Holter to detect PAF in patients after
cerebral ischemia is cost-effective. Given that prolonged
Holter monitoring detects a higher number of new cases
with PAF [35–37], the improved cost-effectiveness is
attributable to the fact that these newly detected patients
benefit from warfarin therapy to prevent stroke recurrence
which in turns saves future costs.
Kamel and colleagues [38] previously examined the
effect of an additional 7 days of outpatient cardiac moni-
toring vs. standard care to detect PAF after IS in the US. In
this analysis, the detection rate of PAF was estimated to be
5.9 % using outpatient monitoring which resulted in an
incremental cost-effectiveness ratio of 13,000 $/QALY,
considerably below a threshold of 50,000 $ per QALY
usually considered cost-effective [38, 39]. A more realistic
scenario, for instance, a scenario with a higher detection
rate of PAF by 7-d-Holter ECG improves the cost-effec-
tiveness to 5,090 $/QALY gained [40], comparable to the
data of our study. Instead of extrapolating trial data of non-
continuous ECG recordings to estimate the yield of 7-d-
Holter, we used actual observations from the Find-AF trial
that offered intra-individual comparison of detection rates
for 24-h, 48-h, and 7-d-Holter [7] in an unselected cohort
of patients with cerebral ischemia. Furthermore, we pro-
spectively assessed incremental costs for the performance
of 7-d-Holter instead of 24-h-Holter in a subgroup of
patients at the end of the FIND-AF trial, i.e., on top of the
learning-curve for this method. In this respect, we believe
that our analysis is based on solid and reliable data and our
results are definitely supportive of the analysis by Kamel
[38]. However in our base case, 7-d-Holter was not only
cost-effective, but actually dominated the 24-h-Holter and
remained highly cost-effective in the most unfavorable
constellations on sensitivity analyses. In addition to sup-
porting Kamel’s analysis with an alternative model based
on clinical data, our analysis was performed for a different
healthcare system (i.e., the German).
Our model predicts mean undiscounted lifetime costs for
patients after the first ever IS or TIA of about 46,000 € and,
therefore, slightly lower than those previously reported by
Kolominsky-Rabas with 50,507 €. Compared to 7.3 years
as reported by Kolominsky-Rabas, mean undiscounted life
expectancy as predicted by our model ranged from 7.77 to
7.79 years [3]. These roughly similar figures give some
external validation for our model.
To project IS recurrence, we used variables primarily
based on values reported in the ACTIVE W trial [14]. To
account for varying risks in PAF-positive and PAF-nega-
tive patients and to display the efficacy of warfarin and
aspirin therapy within these cohorts, relative risks were
used as reported in the literature [6, 15].
Regarding hemorrhagic complications of OAC treat-
ment, we used the annual rate for ICH for patients with prior
stroke or TIA taken from the RELY trial [18] and applied
the relative risk ASS vs. OAC to project this event rate for
ASS-treated patients [15, 18]. Other hemorrhagic compli-
cations such as abdominal or gastrointestinal bleeding were
not included in our analysis. Furthermore, we assumed that
a detection of PAF by Holter monitoring results in a change
of treatment to OAC therapy in any case, although contra-
indications of oral anticoagulation may be present in some
cases. These points therefore give some limitation to our
analyses. However, given these limitations and the fact that
newer anticoagulation drugs (NOACs) have just recently
emerged to the market, which may even further reduce
stroke recurrence in patients with AF with a similar or even
lower risk for cerebral bleedings [41], prolonged Holter
monitoring might became even more cost-effective.
Of note, the use of routine TTE to rule out PAF and to
selectively apply the 7-d-Holter to a subgroup did not
increase the cost-effectiveness ratio, due to the false-neg-
ative patients missed in this approach. Because these 2.2 %
of patients would have been treated erroneously with
antiplatelet therapy only, they would have had a higher risk
882 Clin Res Cardiol (2013) 102:875–884
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of dying from recurrent events and, therefore, a reduction
in cumulative quality-adjusted life expectancy. In sensi-
tivity analyses, the TTE/7-d-Holter became the dominant
strategy beyond a negative predictive value of 98.9 %. It
should be noted that both false-negative patients in Find-
AF only had one very short episode (about 40–45 s) of
PAF on the 7-d-Holter. Because some might argue that
PAF has only been shown to increase the risk of throm-
boembolism when episodes of at least 5–6 min have been
documented, interpretation of our results would then have
to be modified, as TTE would preselect with 100 % neg-
ative predictive value, making the TTE/7-d-Holter the
dominant diagnostic strategy.
Conclusions
The use of a 7-d-Holter as opposed to a standard 24-h-
Holter in patients with cerebral ischemia is cost-effective
across a wide range of variation of key variables and model
input data.
Conflict of interest Research Grant: Rolf Wachter is a principal
investigator (local) of the CRYSTAL-AF study, sponsored by Med-
tronic ([$10 k). Speakers’ Bureau: Rolf Wachter has received pay-
ment for speakers’ bureau appointments by Medtronic (\$10 k).
Research Grant: for the Ex-DHF study ([$10 k). Speakers’ Bureau:
Novartis, Pfizer, Servier, BG Medicine, Berlin Chemie AG (\$ 10k).
The remaining all other authors have no conflicts of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Evers SM, Struijs JN, Ament AJ, van Genugten ML, Jager JH,
van den Bos GA (2004) International comparison of stroke cost
studies. Stroke 35(5):1209–1215. doi:10.1161/01.STR.00001258
60.48180.48
2. Saka O, McGuire A, Wolfe C (2009) Cost of stroke in the United
Kingdom. Age Ageing 38(1):27–32. doi:10.1093/ageing/afn281
3. Kolominsky-Rabas PL, Heuschmann PU, Marschall D, Emmert
M, Baltzer N, Neundorfer B, Schoffski O, Krobot KJ (2006)
Lifetime cost of ischemic stroke in Germany: results and national
projections from a population-based stroke registry: the Erlangen
stroke project. Stroke 37(5):1179–1183. doi:10.1161/01.STR.
0000217450.21310.90
4. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang
MC, Hylek EM, Schulman S, Go AS, Hughes M, Spencer FA,
Manning WJ, Halperin JL, Lip GY (2012) Antithrombotic ther-
apy for atrial fibrillation: antithrombotic therapy and prevention
of thrombosis, 9th ed: American College of Chest Physicians
Evidence-Based Clinical Practice Guidelines. Chest 141(2 Sup-
pl):e531S–e575S. doi:10.1378/chest.11-2304
5. Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M,
Neumaier S, Glahn J, Brandt T, Hacke W, Diener HC (2001) Risk
factors, outcome, and treatment in subtypes of ischemic stroke:
the German stroke data bank. Stroke 32(11):2559–2566
6. Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an
independent risk factor for stroke: the Framingham Study. Stroke
22(8):983–988
7. Stahrenberg R, Weber-Kruger M, Seegers J, Edelmann F, Lahno
R, Haase B, Mende M, Wohlfahrt J, Kermer P, Vollmann D,
Hasenfuss G, Groschel K, Wachter R (2010) Enhanced detection
of paroxysmal atrial fibrillation by early and prolonged continu-
ous holter monitoring in patients with cerebral ischemia pre-
senting in sinus rhythm. Stroke 41(12):2884–2888. doi:10.1161/
STROKEAHA.110.591958
8. Crystal E, Connolly SJ (2004) Role of oral anticoagulation in
management of atrial fibrillation. Heart 90(7):813–817. doi:10.
1136/hrt.2003.02164290/7/813
9. Hart RG, Halperin JL, Pearce LA, Anderson DC, Kronmal RA,
McBride R, Nasco E, Sherman DG, Talbert RL, Marler JR (2003)
Lessons from the stroke prevention in atrial fibrillation trials. Ann
Intern Med 138(10):831–838. doi:200305200-00011
10. Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: anti-
thrombotic therapy to prevent stroke in patients who have non-
valvular atrial fibrillation. Ann Intern Med 146(12):857–867.
doi:146/12/857
11. Stahrenberg R, Edelmann F, Haase B, Lahno R, Seegers J,
Weber-Kruger M, Mende M, Wohlfahrt J, Kermer P, Vollmann
D, Hasenfuss G, Groschel K, Wachter R (2011) Transthoracic
echocardiography to rule out paroxysmal atrial fibrillation as a
cause of stroke or transient ischemic attack. Stroke 42:3643–3645
12. Sonnenberg FA, Beck JR (1993) Markov models in medical
decision making: a practical guide. Med Decis Making 13(4):
322–338
13. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D,
Hohnloser SH, Hindricks G, Kirchhof P, Bax JJ, Baumgartner H,
Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C,
Hasdai D, Hoes A, Knuuti J, Kolh P, McDonagh T, Moulin C,
Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M,
Torbicki A, Vahanian A, Windecker S, Vardas P, Al-Attar N,
Alfieri O, Angelini A, Blomstrom-Lundqvist C, Colonna P, De
Sutter J, Ernst S, Goette A, Gorenek B, Hatala R, Heidbuchel H,
Heldal M, Kristensen SD, Le Heuzey JY, Mavrakis H, Mont L,
Filardi PP, Ponikowski P, Prendergast B, Rutten FH, Schotten U,
Van Gelder IC, Verheugt FW (2012) 2012 focused update of the
ESC guidelines for the management of atrial fibrillation: an
update of the 2010 ESC Guidelines for the management of atrial
fibrillation * Developed with the special contribution of the
European Heart Rhythm Association. Eur Heart J. doi:10.1093/
eurheartj/ehs253
14. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrol-
avicius S, Yusuf S (2006) Clopidogrel plus aspirin versus oral
anticoagulation for atrial fibrillation in the Atrial fibrillation
Clopidogrel Trial with Irbesartan for prevention of Vascular
Events (ACTIVE W): a randomised controlled trial. Lancet
367(9526):1903–1912. doi:10.1016/S0140-6736(06)68845-4
15. van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S,
Petersen P, Koudstaal PJ, Chang Y, Hellemons B (2002) Oral
anticoagulants vs aspirin in nonvalvular atrial fibrillation: an
individual patient meta-analysis. JAMA 288(19):2441–2448 pii:
jcc20007
16. Sullivan PW, Arant TW, Ellis SL, Ulrich H (2006) The cost
effectiveness of anticoagulation management services for patients
with atrial fibrillation and at high risk of stroke in the US.
Pharmacoeconomics 24(10):1021–1033 pii: 24109
17. O’Brien CL, Gage BF (2005) Costs and effectiveness of ximel-
agatran for stroke prophylaxis in chronic atrial fibrillation. JAMA
293(6):699–706. doi:10.1001/jama.293.6.699
Clin Res Cardiol (2013) 102:875–884 883
123
18. Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA,
Yang S, Xavier D, Di Pasquale G, Yusuf S (2010) Dabigatran
compared with warfarin in patients with atrial fibrillation and
previous transient ischaemic attack or stroke: a subgroup analysis
of the RE-LY trial. Lancet Neurol 9(12):1157–1163. doi:10.1016/
S1474-4422(10)70274-X
19. Ariesen MJ, Claus SP, Rinkel GJ, Algra A (2003) Risk factors for
intracerebral hemorrhage in the general population: a systematic
review. Stroke 34(8):2060–2065. doi:10.1161/01.STR.0000080678.
09344.8D
20. Hart RG, Boop BS, Anderson DC (1995) Oral anticoagulants and
intracranial hemorrhage facts and hypotheses. Stroke 26(8):
1471–1477
21. Chambers MG, Koch P, Hutton J (2002) Development of a
decision-analytic model of stroke care in the United States and
Europe. Value Health 5(2):82–97. doi:10.1046/j.1524-4733.2002.
52011.x
22. Briggs A, Sculpher M (1998) An introduction to Markov mod-
elling for economic evaluation. Pharmacoeconomics 13(4):
397–409
23. Landesweite Basisfallwerte (2013) Verband der Ersatzkassen e.
V. http://wwwvdekcom/vertragspartner/Krankenhaeuser/DRG/
landesbasisfallwerte/2_lbfw_2005_2011_epdf. Accessed 10
June 2013
24. Begleitforschung gem § 17b Abs. 8 KHG (2013) InEK—Institut
fu¨r das Entgeltsystem im Krankenhaus. http://www.g-drg.de/cms/
Begleitforschung_gem._17b_Abs._8_KHG. Accessed 13 June
2013
25. Schilling M, Kiefer R, Busse O (2013) Kodierleitfaden Schla-
ganfall der DSG und DGN 2011. http://www.idrg.de/uploads/
media/Kodierleitfaden_DSG_DGN_2011_Schlaganfall.pdf. Acces-
sed 14 June 2013
26. Webgrouper DRG Research Group Medizinisches Management
(2013) website: Universita¨tsklinikum Mu¨nster. http://drg.uni-
muenster.de/index.php. Accessed 14 June, 2013
27. Bru¨ggenju¨rgen B, Rupprecht H, Willich S, Spannagl M, Ehlken
B, Smala A, Berger K, Diener H (2005) Cost of atherothrombotic
diseases-myocardial infarction, ischaemic stroke and peripheral
arterial occlusive disease-in Germany. J Public Health
13:216–224
28. Hein L (2010) Antikoagulantien und Thrombozytenaggregation-
shemmer. In: Arzneiverordnungs-Report 2010: Aktuelle Daten.
Kosten, Trends Und Kommentare. Springer, Heidelberg,
pp 409–424
29. A¨rztegeha¨lter im Vergleich (2013) website: Vereinigung der
kommunalen Arbeitgeberverba¨nde. http://wwwvkade/media/exe/
59/5e98017fbd2136876f289d29949ebc35/110908_vergleich-
aerzeteentgeltepdf. Accessed 10 June 2013
30. Tauch J (2003) Personalbedarfsermittlung im Krankenhaus-Per-
sonalbedarfsermittlung im DRG-Zeitalter, 5th edn., edn. Gu¨ter-
sloher Organisationsberatung, Gu¨tersloh
31. Gage BF, Cardinalli AB, Albers GW, Owens DK (1995) Cost-
effectiveness of warfarin and aspirin for prophylaxis of stroke in
patients with nonvalvular atrial fibrillation. JAMA 274(23):
1839–1845
32. Tengs TO, Lin TH (2003) A meta-analysis of quality-of-life
estimates for stroke. Pharmacoeconomics 21(3):191–200 pii:
210304
33. Haacke C, Althaus A, Spottke A, Siebert U, Back T, Dodel R
(2006) Long-term outcome after stroke: evaluating health-related
quality of life using utility measurements. Stroke 37(1):193–198.
doi:10.1161/01.STR.0000196990.69412.fb
34. Christensen MC, Mayer S, Ferran JM (2009) Quality of life after
intracerebral hemorrhage: results of the factor seven for acute
hemorrhagic stroke (FAST) trial. Stroke 40(5):1677–1682.
doi:10.1161/STROKEAHA.108.538967
35. Liao J, Khalid Z, Scallan C, Morillo C, O’Donnell M (2007)
Noninvasive cardiac monitoring for detecting paroxysmal atrial
fibrillation or flutter after acute ischemic stroke: a systematic
review. Stroke 38(11):2935–2940. doi:10.1161/STROKEAHA.
106.478685
36. Barthelemy JC, Feasson-Gerard S, Garnier P, Gaspoz JM, Da
Costa A, Michel D, Roche F (2003) Automatic cardiac event
recorders reveal paroxysmal atrial fibrillation after unexplained
strokes or transient ischemic attacks. Ann Noninvasive Electro-
cardiol 8(3):194–199 pii:08305
37. Jabaudon D, Sztajzel J, Sievert K, Landis T, Sztajzel R (2004)
Usefulness of ambulatory 7-day ECG monitoring for the detec-
tion of atrial fibrillation and flutter after acute stroke and transient
ischemic attack. Stroke 35(7):1647–1651. doi:10.1161/01.STR.
0000131269.69502.d901.STR.0000131269.69502.d9
38. Kamel H, Hegde M, Johnson DR, Gage BF, Johnston SC (2010)
Cost-effectiveness of outpatient cardiac monitoring to detect
atrial fibrillation after ischemic stroke. Stroke 41(7):1514–1520.
doi:10.1161/STROKEAHA.110.582437
39. Gold JS, Russel LB, Weinstein MC (1996) Cost-effectiveness in
Health and Medicine. Oxford University Press, New York
40. Wachter R, Stahrenberg R, Groschel K (2011) Letter by Wachter
et al regarding article ‘‘Cost-effectiveness of outpatient cardiac
monitoring to detect atrial fibrillation after ischemic stroke’’.
Stroke 42(3):e36–e37. doi:10.1161/STROKEAHA.110.604173
Author reply
41. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J,
Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S,
Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener
HC, Joyner CD, Wallentin L (2009) Dabigatran versus warfarin
in patients with atrial fibrillation. N Engl J Med 361(12):
1139–1151. doi:10.1056/NEJMoa0905561
42. Bruggenjurgen B, Rossnagel K, Roll S, Andersson FL, Selim D,
Muller-Nordhorn J, Nolte CH, Jungehulsing GJ, Villringer A,
Willich SN (2007) The impact of atrial fibrillation on the cost of
stroke: the berlin acute stroke study. Value Health 10(2):
137–143. doi:10.1111/j.1524-4733.2006.00160.x
43. Weimar C, Weber C, Wagner M, Busse O, Haberl RL, Lauter-
bach KW, Diener HC (2003) Management patterns and health
care use after intracerebral hemorrhage. a cost-of-illness study
from a societal perspective in Germany. Cerebrovasc Dis
15(1–2):29–36 pii:ced15029
884 Clin Res Cardiol (2013) 102:875–884
123
